Physician profile
Paval Romano
NPI 1174623136
$18,077.05
in general payments reported to CMS, 2019-2025
61 companies · $2,305 in 2025
The $2,305 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,080 · 2020: $1,649 · 2021: $3,176 · 2022: $2,560 · 2023: $2,855 · 2024: $2,452 · 2025: $2,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,612.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,599.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,300.72 | 2019-2025 | |
| Novo Nordisk INC | $1,170.70 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $1,122.04 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $1,044.32 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,011.37 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $945.89 | 2019-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $847.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $791.03 | 2019-2025 | Farxiga, Airsupra, Wainua |
| Amarin Pharma, INC. | $763.03 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $646.38 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $644.79 | 2020-2024 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $528.97 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $480.31 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $465.94 | 2020-2025 | Nexletol |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $276.68 | 2019-2023 | Veozah, Lexiscan |
| Bayer Healthcare Pharmaceuticals INC. | $270.55 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $265.53 | 2023-2025 | Edarbi, Edarbyclor, Edarbyclor |
| Sumitomo Pharma America, INC. | $263.37 | 2024-2025 | Gemtesa |
| Eisai INC. | $246.57 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $246.43 | 2022-2023 | Quviviq |
| Abbvie INC. | $219.35 | 2019-2025 | |
| Biotronik INC. | $215.56 | 2021 | |
| Arbor Pharmaceuticals, INC. | $191.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $189.55 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $181.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $178.51 | 2019-2024 | Evkeeza |
| Medtronic, INC. | $168.61 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $158.53 | 2019-2023 | Livalo, Seglentis |
| Sanofi Pasteur INC. | $150.12 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $148.48 | 2024 | Arcalyst |
| Atricure, INC. | $99.40 | 2019 | |
| Lilly USA, LLC | $95.95 | 2019-2024 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $95.82 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $87.95 | 2023-2024 | Optimizer, Optimizer |
| Kestra Medical Technology Services, INC. | $81.31 | 2024-2025 | Assure Wcd |
| Lundbeck LLC | $72.94 | 2019-2020 | |
| Exact Sciences Corporation | $68.60 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $54.32 | 2024 | Korlym |
| Bardy Diagnostics, INC. | $53.88 | 2022 | |
| Heartflow, INC. | $53.10 | 2023-2025 | Ffrct |
| Inspire Medical Systems, INC. | $49.62 | 2024-2025 | Inspire |
| Scpharmaceuticals INC. | $49.36 | 2023-2024 | |
| Seqirus USA INC | $49.04 | 2024 | Fluad, Flucelvax |
| Daiichi Sankyo INC. | $45.34 | 2024 | Injectafer |
| Avvisto Therapeutics, LLC | $39.65 | 2024 | Cycloset |
| Gilead Sciences, INC. | $37.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.85 | 2024 | Cycloset |
| Currax Pharmaceuticals LLC | $35.67 | 2020 | |
| Tandem Diabetes Care, INC. | $28.24 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Axsome Therapeutics, INC. | $25.51 | 2025 | Auvelity |
| Kiniksa Pharmaceuticals, LTD. | $24.44 | 2023 | Arcalyst |
| Amryt Pharma Holdings LTD | $22.53 | 2021 | |
| Intra-Sana Laboratories | $21.50 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Bridgebio Pharma, INC. | $20.23 | 2025 | Attruby |
| Medicomp INC | $19.89 | 2024 | Telepatch Cardiac Monitor |
| Ibsa Pharma INC. | $19.58 | 2025 | Licart, Flector, Tirosint |
| Althera Pharmaceuticals LLC | $16.91 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2019 | |
| Vistapharm, INC. | $13.08 | 2021 | |
| Allergan, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paval Romano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.